Research graph
References from Development and validation of a clinical-pharmacogenomic prediction model for clopidogrel-related high on-treatment platelet reactivity in patients with coronary artery disease. Local targets link to admitted publications; unresolved targets remain external evidence.
A novel machine learning model to predict high on-treatment platelet reactivity on clopidogrel in Asian patients after percutaneous coronary intervention
10.1007/s11096-023-01638-1 · 2024 · External reference
Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score
10.1016/j.jcin.2020.01.226 · 2020 · External reference
Development and validation of a novel tool for the prediction of clopidogrel response in Chinese acute coronary syndrome patients: the GeneFA score
10.3389/fphar.2022.854867 · 2022 · External reference
Pharmacogenomic polygenic model of clopidogrel predicts recurrent ischemic events in Chinese patients with coronary artery disease
10.1016/j.clinthera.2024.06.019 · 2024 · External reference
Impact of CYP2C19 genotype Status on clinical outcomes in patients with symptomatic coronary artery disease, stroke, and peripheral arterial disease: a systematic review and meta-analysis
10.1007/s40265-024-02076-7 · 2024 · External reference
Redictive value of serial platelet function testing on outcome in patients undergoing complex percutaneous coronary intervention
10.3760/cma.j.issn.0253-3758.2017.09.008 · 2017 · External reference
Clopidogrel pharmacogenetics
10.1161/circinterventions.119.007811 · 2019 · External reference
Impact of the ABCD-GENE score on clopidogrel clinical effectiveness after PCI: a multi-site, real-world investigation
10.1002/cpt.2612 · 2022 · External reference
Genotype-Guided antiplatelet therapy. JACC review topic of the week
10.1016/j.jacc.2024.06.038 · 2024 · External reference
Efficacy and safety of concomitant use of proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: a systematic review and meta-analysis
10.3389/fphar.2022.1021584 · 2023 · External reference
Construction of a machine learning-based clopidogrel resistance risk prediction model
10.1007/s12012-025-10026-2 · 2025 · External reference
CYP2C19 Genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association
10.1161/cir.0000000000001257 · 2024 · External reference
Evaluating the effect of estimating renal function with the CKD-EPI 2021 equation on the ABCD-GENE score for clopidogrel response prediction
10.1002/cpt.3385 · 2024 · External reference
Differential impact of clinical and genetic factors on high platelet reactivity in patients with coronary artery disease treated with clopidogrel and prasugrel
10.5551/jat.63035 · 2022 · External reference
CYP2C19 Genotype-Guided antiplatelet therapy after percutaneous coronary intervention in diverse clinical settings
10.1161/jaha.121.024159 · 2022 · External reference
Rates of 30-day and 90-day readmission between genotype-optimal and genotype-suboptimal antiplatelet therapy prescribing after percutaneous coronary intervention
10.1016/j.amjcard.2023.06.090 · 2023 · External reference
Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis
10.3389/fphar.2025.1621327 · 2025 · External reference
Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial
10.1016/s0140-6736(24)00473-2 · 2024 · External reference
Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans
10.1007/s00228-022-03304-3 · 2022 · External reference
Association between Q192R PON1 genetic polymorphism and major adverse cardiovascular events in patients treated with clopidogrel: an updated meta-analysis
10.1080/14740338.2023.2212152 · 2023 · External reference
A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI
10.1056/nejmoa1907096 · 2019 · External reference
Genetic and clinical determinants of MACE and haemorrhage in antiplatelet therapy: insights from pharmacogenomic analysis
10.3389/fcvm.2025.1572389 · 2025 · External reference
